论文部分内容阅读
采用小牛胸腺肽注射液（大连白玉制药厂）联合抗乙肝免疫核糖核酸（吉林大学洮南联合制药厂）治疗组与抗乙肝免疫核糖核酸对照组治疗慢性乙型肝炎作了比较分析，结果示治疗组ＨＢｅＡｇ转阴率为７１％。ＨＢＶ－ＤＮＡ转阴率为７５％，ＡＬＴ复常率为８５％。与对照组比较有显著性差异（Ｐ＜０．０１），治疗组优于对照组。因此认为小牛胸腺肽联合抗乙肝免疫核糖核酸对治疗慢性乙型肝炎及ＨＢｅＡｇ的转阴率有明显的疗效。
Using calf thymus peptide injection (Dalian white jade pharmaceutical factory) combined with anti-hepatitis B immune ribonucleic acid (Jilin University Taonan joint pharmaceutical factory) treatment group and anti-hepatitis B immune ribonucleic acid control group for chronic hepatitis B were analyzed, the results showed that treatment Group HBeAg negative rate of 71%. HBV-DNA negative rate was 75%, ALT normalization rate was 85%. Compared with the control group, there was significant difference (P <0.01), the treatment group was better than the control group. Therefore, the combination of calf thymosin and anti-HBV DNA in the treatment of chronic hepatitis B and HBeAg negative rate has a significant effect.